Stakeholders

“Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.”

Oslo University Hospital (OUH)

The Department of Cellular Therapy at Oslo University Hospital is home to one of the largest GMP certified academic facilities to produce cellular products in Europe and one of the few European sites that participated in Novartis’ trials with CD19-specific CAR T cells and later other companies. The department has 7 cleanrooms for therapy production, a leukapheresis unit and a quality assurance laboratory. This is the only facility in Norway that has the infrastructure and expertise able to perform clinical scale development of this type of ACT. 

Oslo Cancer Cluster, (OCC)

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

SINTEF

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Thermo Fisher Scientific

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Project Steering Group

Name, Title, Org
Name, Title, Org
Name, Title, Org
Name, Title, Org

Project Lead:

Else Marit Inderberg is group leader at the Translational Research Unit, Department of Cellular Therapy.  She has served as Head of the Immunomonitoring Unit since XXX and is currently overseeing 12 ongoing clinical studies (both academic and industry-driven). 

Project Lead's Team

Sébastien Wälchli

Sébastien Wälchli is group leader at the Translational Research Unit, Department of Cellular Therapy. He is an expert in molecular biology and biotechnology and has made key discoveries in TCR and CAR development. He provides molecular tools for extended immunomonitoring in academic clinical studies. He is the inventor for >15 patents and co-founder of Zelluna Immunotherapy AS.  

Dag Josefsen

Dag Josefsen, Head of Department of Cellular Therapy.  He has expertise in cellular therapy, stem cell research, GMP requirements and directives for cellular therapy and is a certified JACIE (Joint Accreditation Committee of the International Society for Cellular Therapy and EBMT) inspector. 

Anna Winge-Main

Anna Winge-Main is Chief Consultant in Oncology, a researcher (50%) working on the development of T-cell therapy in melanoma at the Department of Cellular Therapy.   

Acknowledgments:

The Research Council of Norway​

 molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt mollitia animi, id est laborum et dolorum fuga. Et harum quidem rerum facilis est et expedita distinctio. Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis au